{"id":"gadoteric-acid-meglumine-salt","safety":{"commonSideEffects":[{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Gadolinium retention (rare)"}]},"_chembl":{"chemblId":"CHEMBL3833326","moleculeType":"Small molecule","molecularWeight":"558.65"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Gadoteric acid is a macrocyclic gadolinium chelate complex that distributes in the extracellular space and increases signal intensity in T1-weighted MRI images. The paramagnetic gadolinium ion alters the relaxation properties of nearby water molecules, enabling improved visualization of anatomical structures and pathological lesions during MRI examinations.","oneSentence":"Gadoteric acid meglumine salt is a gadolinium-based contrast agent that enhances magnetic resonance imaging (MRI) by shortening the T1 relaxation time of water protons in tissues.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:46:57.318Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"MRI contrast enhancement for central nervous system imaging"},{"name":"MRI contrast enhancement for body imaging"}]},"trialDetails":[{"nctId":"NCT04776187","phase":"PHASE4","title":"Safety Evaluation of Linear and Macrocyclic Gadolinium Based Contrast Agents for Patients With Mild to Moderate Renal Insufficiency Undergoing Enhanced Magnetic Resonance Imaging","status":"UNKNOWN","sponsor":"The Central Hospital of Lishui City","startDate":"2021-03-01","conditions":"Nephrogenic Fibrosing Dermopathy","enrollment":600}],"_emaApprovals":[],"_faersSignals":[{"count":1,"reaction":"ADRENOMEGALY"},{"count":1,"reaction":"ASCITES"},{"count":1,"reaction":"DIARRHOEA"},{"count":1,"reaction":"GRANULOCYTOPENIA"},{"count":1,"reaction":"HEPATIC CYST"},{"count":1,"reaction":"NEOPLASM PROGRESSION"},{"count":1,"reaction":"OEDEMA PERIPHERAL"},{"count":1,"reaction":"PNEUMONIA"},{"count":1,"reaction":"PNEUMONITIS"},{"count":1,"reaction":"RENAL CYST"}],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Gadoteric Acid Meglumine Salt","genericName":"Gadoteric Acid Meglumine Salt","companyName":"The Central Hospital of Lishui City","companyId":"the-central-hospital-of-lishui-city","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Gadoteric acid meglumine salt is a gadolinium-based contrast agent that enhances magnetic resonance imaging (MRI) by shortening the T1 relaxation time of water protons in tissues. Used for MRI contrast enhancement for central nervous system imaging, MRI contrast enhancement for body imaging.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}